Effect of dopaminergic medications on Montreal Cognitive Assessment in Parkinson's disease patients

IF 3.1 3区医学 Q2 CLINICAL NEUROLOGY

Parkinsonism & related disorders Pub Date : 2025-07-07 DOI:10.1016/j.parkreldis.2025.107951

Tao Xie , Chuanhong Liao , Jonathan Bundy , Widad Abou Chaar , Hanna Lancerio , Maureen Lacy , Kaitlin Seibert , Brian C. Chiu , Mahesh Padmanaban

{"title":"Effect of dopaminergic medications on Montreal Cognitive Assessment in Parkinson's disease patients","authors":"Tao Xie , Chuanhong Liao , Jonathan Bundy , Widad Abou Chaar , Hanna Lancerio , Maureen Lacy , Kaitlin Seibert , Brian C. Chiu , Mahesh Padmanaban","doi":"10.1016/j.parkreldis.2025.107951","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>It is unknown whether dopaminergic medications affect the overall and individual cognitive function scores of the Montreal Cognitive Assessment (MoCA) in White and Black patients with Parkinson's disease (PD). A study on this would have significant implications in clinical practice and research.</div></div><div><h3>Methods</h3><div>We compared the overall and individual cognitive function scores of the MoCA and the Unified PD Rating Scale motor (UPDRS-III) scores at medications Off/On status in White patients and Black patients with PD in any individual or combined groups. We also compared other motor, non-motor (UPDRS-I/-II/-IV, depression/anxiety) and quality of life (PD-QoL-39) scale scores between White patients and Black patients.</div></div><div><h3>Results</h3><div>In 68 patients recruited (40/28 White/Black, comparable in ages and disease durations), dopaminergic medications did not make significant differences in overall MoCA scores but significantly improved the UPDRS-III motor scores at similar magnitudes in all groups. There was a slight improvement in naming and abstraction and worsening in delayed recall when on medications among these groups. There was no difference in other motor, non-motor, and QoL scores, except less social support in Black patients compared to White patients.</div></div><div><h3>Conclusions</h3><div>Dopaminergic medications do not significantly affect the overall MoCA score (except a few individual cognitive functions) in White and Black patients with PD despite significant improvement in motor symptoms in all groups in this study. There is no difference in other motor, non-motor, and QoL scores, except less social support in Black patients compared to White patients. This study has significant implications in practice and research.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"138 ","pages":"Article 107951"},"PeriodicalIF":3.1000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Parkinsonism & related disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1353802025006923","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

It is unknown whether dopaminergic medications affect the overall and individual cognitive function scores of the Montreal Cognitive Assessment (MoCA) in White and Black patients with Parkinson's disease (PD). A study on this would have significant implications in clinical practice and research.

Methods

We compared the overall and individual cognitive function scores of the MoCA and the Unified PD Rating Scale motor (UPDRS-III) scores at medications Off/On status in White patients and Black patients with PD in any individual or combined groups. We also compared other motor, non-motor (UPDRS-I/-II/-IV, depression/anxiety) and quality of life (PD-QoL-39) scale scores between White patients and Black patients.

Results

In 68 patients recruited (40/28 White/Black, comparable in ages and disease durations), dopaminergic medications did not make significant differences in overall MoCA scores but significantly improved the UPDRS-III motor scores at similar magnitudes in all groups. There was a slight improvement in naming and abstraction and worsening in delayed recall when on medications among these groups. There was no difference in other motor, non-motor, and QoL scores, except less social support in Black patients compared to White patients.

Conclusions

Dopaminergic medications do not significantly affect the overall MoCA score (except a few individual cognitive functions) in White and Black patients with PD despite significant improvement in motor symptoms in all groups in this study. There is no difference in other motor, non-motor, and QoL scores, except less social support in Black patients compared to White patients. This study has significant implications in practice and research.

查看原文本刊更多论文

多巴胺能药物对帕金森病患者蒙特利尔认知评估的影响

目前尚不清楚多巴胺能药物是否会影响白人和黑人帕金森病患者蒙特利尔认知评估（MoCA）的整体和个体认知功能评分。这方面的研究对临床实践和研究具有重要意义。方法比较白人和黑人PD患者在药物关闭/打开状态下的MoCA和统一PD评定量表运动（UPDRS-III）的整体和个体认知功能评分。我们还比较了白人患者和黑人患者的其他运动、非运动（UPDRS-I/-II/-IV，抑郁/焦虑）和生活质量（PD-QoL-39）量表得分。结果68例患者（40/28例白种人/黑种人，年龄和病程相当），多巴胺能药物对MoCA总分无显著影响，但对UPDRS-III运动评分有相似程度的显著改善。在这些小组中，在命名和抽象方面有轻微的改善，在延迟回忆方面有恶化。除了黑人患者的社会支持比白人患者少外，其他运动、非运动和生活质量评分没有差异。结论多巴胺能药物对白人和黑人PD患者总体MoCA评分（除少数个体认知功能外）没有显著影响，尽管本研究中所有组的运动症状均有显著改善。除了黑人患者的社会支持比白人患者少外，其他运动、非运动和生活质量评分没有差异。本研究具有重要的实践和研究意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Parkinsonism & related disorders 医学-临床神经学

CiteScore

6.20

自引率

4.90%

发文量

292

审稿时长

39 days

期刊介绍： Parkinsonism & Related Disorders publishes the results of basic and clinical research contributing to the understanding, diagnosis and treatment of all neurodegenerative syndromes in which Parkinsonism, Essential Tremor or related movement disorders may be a feature. Regular features will include: Review Articles, Point of View articles, Full-length Articles, Short Communications, Case Reports and Letter to the Editor.